Target Test, which is the first FDA-approved next-generation sequencing-based companion diagnostic method for diagnosing EGFR mutation, ALK rearrangement, ROS1 rearrangement, and BRAF V600E mutation in patients with NSCLC, was performed without complications using our methods. Here, ALK is linked to non-small cell lung carcinoma.